Healthcare Industry News: Echo Therapeutics
News Release - October 11, 2011
Echo Therapeutics Hires Product Development Management ExecutivePHILADELPHIA, Oct. 11, 2011 -- (Healthcare Sales & Marketing Network) -- Echo Therapeutics, Inc. (Nasdaq:ECTE ), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that Samir Farah, who has more than fifteen years of medical product design and development experience, has joined Echo Therapeutics' management team at a critical stage in product development and company growth.
Samir Farah joins as Vice President of Product Development executing Echo's product roadmap strategy and reports directly to Marshall ("Mac") Deweese who was recently appointed Senior Vice President of Operations.
"Samir's wealth of knowledge and product development experience will help support Echo's goal of attaining FDA marketing clearance of our Symphony tCGM System," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We are extremely pleased to have such a highly valuable, proven industry leader join the company as we move toward Symphony's commercialization. I have great confidence in Samir's ability to take us into the next phase of our product life-cycle."
Mr. Farah has over fifteen years of experience in product planning and implementation of medical and commercial products, with a proven track record of leading projects from conceptualization through commercialization. Most recently, Mr. Farah was a Sr. Engineering Manager and acting director at Philips Home Monitoring (division of Philips Healthcare) where he led the product development team of 20 engineers, and provided the technology map and technical direction on multi-product platforms. Prior to that, Mr. Farah led a multi-discipline team in the design and development of a highly integrated and next generation blood glucose system from product definition to product launch at Abbott Laboratories. Mr. Farah has a deep knowledge of FDA and ISO regulatory standards for the design and manufacture of medical devices. He received his B.S. in Electronic Engineering Technology from Wentworth Institute of Technology.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including: the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems; the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems; Echo's ability to secure additional commercial partnering arrangements; risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems; the availability of substantial additional funding to support its research, development and product commercialization activities; and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Forms 10-Q, and its Current Reports on Forms 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
Source: Echo Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.